Understanding the binding mechanism between MKK3 and RAGE may be useful for the development of inhibitors targeting MKK3 and RAGE, providing novel insights into treating diabetes-associated neurodegenerative diseases. This evidence concerns the gene MAP2K3 and neurodegenerative disease.